Welcome to our dedicated page for ClearPoint Neuro SEC filings (Ticker: CLPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ClearPoint Neuro, Inc. filings document the company's medical-device and therapy-enabling business, including operating results for its brain and spine navigation platforms, CNS drug-delivery services, and neurocritical-care portfolio after the completed IRRAS Holdings acquisition. Form 8-K reports furnish quarterly and annual results, Regulation FD investor presentations, acquisition-related financial statements, pro forma combined financial information, and material-event disclosures.
Proxy materials cover governance matters, director voting, executive compensation, pay-versus-performance data, and equity-award disclosures. The filing record also includes material agreements, capital-structure disclosure, shareholder voting matters, and clinical or regulatory disclosures tied to the company's regulated neurosurgical products and partnered biologics programs.
ClearPoint Neuro, Inc. (CLPT) reported an insider issuance to director Pascal E. R. Girin: on 10/01/2025 the company issued 315 shares of common stock at a price equal to the closing market price on 9/30/2025, $21.79, as payment of fees under the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan and the Non-Employee Director Compensation Plan. Following the issuance, the reporting person beneficially owns 96,949 shares directly. The Form 4 was signed by an attorney under power of attorney and filed on 10/02/2025.
ClearPoint Neuro, Inc. filed a Form S-8 registration statement to register additional shares of its common stock for issuance under two employee equity plans: the Amended and Restated 2021 Employee Stock Purchase Plan and the Sixth Amended and Restated 2013 Incentive Compensation Plan. The filing incorporates by reference the company’s recent proxy statement, annual report, quarterly reports, and certain current reports, along with the existing S-8 registration statements for these plans. The document also lists the company’s charter and bylaw documents, legal opinions, consents, and power of attorney as exhibits, and is signed by the chief executive officer, chief financial officer, and all directors.
ClearPoint Neuro reported total revenue of $9.2 million for the quarter, up 17% from $7.9 million a year earlier, led by product revenue of $6.0 million (up 21%). Gross profit was $5.6 million with a 60% margin, slightly below prior-year margins. The company recorded a net loss of $5.8 million for the quarter (basic and diluted loss per share $0.21) and a six-month net loss of $11.9 million (EPS $0.42), driven by higher research and development, sales and marketing, and general and administrative expenses.
Liquidity strengthened to $41.5 million in cash and equivalents at June 30, 2025 after a registered direct equity sale that raised ~$3.3 million net and an initial note issuance that provided approximately $28.7 million net. The company entered a Note Purchase Agreement providing up to $105.0 million of potential notes (initial $30.0 million funded) secured by substantially all assets and carrying PIK interest and future revenue-sharing provisions; management states existing cash is sufficient for at least the next twelve months. Accumulated deficit totaled $203.2 million.